News

Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial SUNP’s 1Q earnings were well ahead of JMFe/ street estimates. This outperformance was primarily driven by US generics (ex-Taro) including gRevlimid and healthy specialty sales of USD 232mn notwithstanding seasonality and Mohali/ Halol regulatory issues. The upward trajectory of specialty business continues with increasing volume share of Ilumya and Winlevi (Winlevi has garnered 26% share among top 10 branded drugs). We expect SUNP’s global specialty business to be ~USD 1bn in FY24...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial
Source: JM Financial Institutional Securities
13/08/2023 12:21:34 PM
Stock Picks : Sun Pharmaceuticals Industries Ltd and Bandhan Bank Ltd By ICICI Direct Sun Pharmaceuticals Industries Ltd Buy Sun Pharmaceuticals Industries Ltd @1159-1161; Target 1176.00; Stop Loss 1151.70   Bandhan Bank Ltd Buy Bandhan Bank Ltd @228.80-229.40; Target 233.00; Stop Loss 227.40   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631 &...
Stock Picks : Sun Pharmaceuticals Industries Ltd and Bandhan Bank Ltd By ICICI Direct
Stock Picks : Sun Pharmaceuticals Industries Ltd and Bandhan Bank Ltd By ICICI Direct
Source: ICICI Direct
8/08/2023 10:38:11 AM
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd Clinical progress to drive R&D expense on specialty portfolio Sun Pharma (SUNP) delivered better-than-expected operating performance in 1QFY24. The steady traction in specialty sales, higher US generics sales and controlled opex led to 12% beat on EBITDA. The R&D expense is likely to pick-up over the coming quarter due to progress in major clinical programs. * We raise our earnings estimates by 3.4%/5.0% for FY24/FY25 to factor in: a) better off-take in the US generics, and b) i...
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
5/08/2023 9:43:40 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial SUNP’s 1Q earnings were well ahead of JMFe/ street estimates. This outperformance was primarily driven by US generics (ex-Taro) including gRevlimid and healthy specialty sales of USD 232mn notwithstanding seasonality and Mohali/ Halol regulatory issues. The upward trajectory of specialty business continues with increasing volume share of Ilumya and Winlevi (Winlevi has garnered 26% share among top 10 branded drugs). We expect SUNP’s global specialty business to be ~USD 1bn in FY24...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,255 - JM Financial
Source: JM Financial Institutional Securities Ltd
4/08/2023 1:20:30 PM
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd Clinical progress to drive R&D expense on specialty portfolio * Sun Pharma (SUNP) delivered better-than-expected operating performance in 1QFY24. The steady traction in specialty sales, higher US generics sales and controlled opex led to 12% beat on EBITDA. The R&D expense is likely to pick-up over the coming quarter due to progress in major clinical programs. * We raise our earnings estimates by 3.4%/5.0% for FY24/FY25 to factor in: a) better off-take in the US generics, and b)...
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1,310 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
4/08/2023 10:31:41 AM
India's Sun Pharma posts Q1 profit fall on higher expenses Sun Pharmaceutical Industries posted a nearly 2% fall in its first-quarter profit on Thursday, hurt by a rise in expenses. The company's consolidated net profit after tax stood at 20.23 billion rupees ($244.4 million) for the quarter ended June 30, compared with 20.61 billion rupees a year earlier. Analysts, on average, had expected a profit of 21.38 billion rupees, as per Refinitiv data. ($1 = 82.7825 Indian rupees)
India's Sun Pharma posts Q1 profit fall on higher expenses
India's Sun Pharma posts Q1 profit fall on higher expenses
Source: Reuters
3/08/2023 2:50:16 PM
Sun Pharma gains on looking at high single-digit growth in consolidated topline in FY24 Sun Pharmaceutical Industries is currently trading at Rs. 1142.80, up by 5.05 points or 0.44% from its previous closing of Rs. 1137.75 on the BSE. The scrip opened at Rs. 1138.05 and has touched a high and low of Rs. 1145.00 and Rs. 1126.75 respectively. So far 32475 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1155.00 on 27-Jul-2023 and a 52 week low of Rs. 855.85 on 22-Aug-2022. Last one week high and low o...
Sun Pharma gains on looking at high single-digit growth in consolidated topline in FY24
Sun Pharma gains on looking at high single-digit growth in consolidated topline in FY24
Source: Accord Fintech
31/07/2023 3:27:26 PM
Stock of the day: Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1075 - Religare Broking Sun Pharmaceutical Industries Ltd. * The pharma index has witnessed a trend reversal. Seeing noticeable traction across the pack. * Sunpharma has been consolidating in a range for the last eight months and currently trading at the middle of the band. * The last three weeks pause has result in formation of fresh buying pivot. Expect retest of upper band soon. * We thus recommend creating fresh longs in the mentioned range. Buy Sun Pharmaceutical Industries Ltd CMP 1021....
Stock of the day: Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1075 - Religare Broking
Stock of the day: Buy Sun Pharmaceutical Industries Ltd For Target Rs. 1075 - Religare Broking
Source: Religare Broking Ltd
30/06/2023 10:23:08 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,200 - JM Financial Sun Pharma reported 4Q earnings ahead of JMFe after adjusting for exceptional item of INR 1.7bn. The topline benefited from strong global specialty sales of USD 244mn (incl. USD 6.8mn milestone). The gross margin in 4Q reflects lower API sales and benefits of product mix tilted towards specialty and gRevlimid. The management expects the current gross margin of ~79% to normalize in coming quarters. 4Q reflects full impact of Halol IA and IT security breach issues cushioned by gRevlimid (USD 33...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,200 - JM Financial
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,200 - JM Financial
Source: JM Financial Institutional Securities Ltd
17/06/2023 10:41:18 AM
Buy Sun Pharma Ltd For Target Rs 1,160 - Motilal Oswal Financial Services Launched g-Revlimid in 4QFY23; specialty sales strengthen further   * Sun Pharmaceutical and Industries (SUNP) delivered operational miss for 4QFY23 performance (on ex-milestone income basis), led by higher-thanexpected operational cost. There was a sharp uptick in gross margin, (YoY/QoQ) due to increased share of higher margin products. However, this benefit was offset to some extent due to increased promotional spent in the branded segment. * We reduce our earnings estimate by...
Buy Sun Pharma Ltd For Target Rs 1,160 - Motilal Oswal Financial Services
Buy Sun Pharma Ltd For Target Rs 1,160 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
1/06/2023 2:46:24 PM
Stock Picks : Sun Pharma Ltd and Canara Bank Ltd By ICICI Direct Sun Pharma Ltd Buy Sun Pharma Ltd @973-975 CMP 975.35; Target 988.70; Stop Loss 966.30   Canara Bank Buy Canara Bank @308.50-309.50 CMP 309.70; Target 313.90; Stop Loss 306.30   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above vi...
Stock Picks : Sun Pharma Ltd and Canara Bank Ltd By ICICI Direct
Stock Picks : Sun Pharma Ltd and Canara Bank Ltd By ICICI Direct
Source: ICICI Direct
1/06/2023 12:20:18 PM
Sun Pharmaceutical Industries gains on entering into licensing agreement with Philogen Sun Pharmaceutical Industries is currently trading at Rs. 970.15, up by 10.95 points or 1.14% from its previous closing of Rs. 959.20 on the BSE. The scrip opened at Rs. 966.45 and has touched a high and low of Rs. 978.30 and Rs. 961.60 respectively. So far 47833 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022. Last one week high and low of th...
Sun Pharmaceutical Industries gains on entering into licensing agreement with Philogen
Sun Pharmaceutical Industries gains on entering into licensing agreement with Philogen
Source: Accord Fintech
31/05/2023 1:42:27 PM
India's Sun Pharma posts nearly 30% rise in Q4 profit Sun Pharmaceutical Industries Ltd, India's largest drugmaker by revenue, on Friday reported a 29.6% rise in fourth-quarter profit, as it benefited from lower expenses. The company's consolidated profit before exceptional items and tax rose to 24.11 billion rupees ($291.7 million) for the quarter ended March 31, it said in an exchange filing. Input costs declined 13.2% for the quarter. ($1 = 82.6420 Indian rupees)    
India's Sun Pharma posts nearly 30% rise in Q4 profit
India's Sun Pharma posts nearly 30% rise in Q4 profit
Source: Accord Fintech
26/05/2023 3:12:14 PM
Stock Picks : State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct State Bank of India Ltd Buy State Bank of India Ltd @578.50-579.50 CMP 580.00; Target 587.00; Stop Loss 573.70   Sun Pharma Ltd Buy Sun Pharma Ltd @972-974 CMP 974.00; Target 986.00; Stop Loss 964.70   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631 &nbs...
Stock Picks : State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct
Stock Picks : State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct
Source: ICICI Direct
5/05/2023 11:15:28 AM
US FDA halts India`s Sun Pharma trials on dermatological drug The U.S. Food and Drug Administration (FDA) has asked India's Sun Pharmaceutical Industries Ltd to halt tests on one dose of an experimental dermatological drug due to the potential of blood clots, the company said on Tuesday. The FDA has also said that patients with alopecia areata - an autoimmune condition that results in patchy hair loss - on the 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said. However, there were no thrombotic events, or blood c...
US FDA halts India`s Sun Pharma trials on dermatological drug
US FDA halts India`s Sun Pharma trials on dermatological drug
Source: Reuters
2/05/2023 10:22:59 AM
India`s Sun Pharma flags revenue hit from IT `incident` Indian drugmaker Sun Pharmaceutical Industries Ltd would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" that happened earlier this month. The effect of the incident on the drug major's IT systems included a breach of certain file systems and theft of some company and personal data, Sun Pharma said in a filing late on Sunday. A ransomware group has claimed responsibility for the incident, it added. Sun Pharma, known fo...
India`s Sun Pharma flags revenue hit from IT `incident`
India`s Sun Pharma flags revenue hit from IT `incident`
Source: Reuters
27/03/2023 10:28:02 AM
Sun Pharma moves up on inking pact to acquire 60% stake in Vivaldis Health and Foods Sun Pharmaceutical Industries is currently trading at Rs. 979.95, up by 7.15 points or 0.73% from its previous closing of Rs. 972.80 on the BSE. The scrip opened at Rs. 980.05 and has touched a high and low of Rs. 981.00 and Rs. 963.95 respectively. So far 24819 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022. Last one week high and low of the...
Sun Pharma moves up on inking pact to acquire 60% stake in Vivaldis Health and Foods
Sun Pharma moves up on inking pact to acquire 60% stake in Vivaldis Health and Foods
Source: Accord Fintech
27/03/2023 10:20:06 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1010 - Religare Broking Sun Pharmaceutical Industries Ltd * SUNPHARMA has swiftly rebounded of late after testing its support zone of long term moving averages on the daily chart. * It has attempted to cross the immediate hurdle of medium term moving average (100 EMA), adding to the positivity. * The chart pattern combined with the rise in volumes is pointing towards a steady up move. * We thus suggest initiating fresh longs as per the given levels.   Buy Sun Pharmaceutical Industries Ltd ...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1010 - Religare Broking
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1010 - Religare Broking
Source: Religare Broking Ltd
24/03/2023 11:20:55 AM
Key Stock Ideas: Genesis, Jindal Stainless, Sun Pharma, Mercedes Benz India - ARETE Securities Genesis, IGL to invest Rs 110 cr to set up meter manufacturing plant: Genesis, an arm of Vikas Lifecare Limited (VLF), has inked a pact with Indraprastha Gas Limited (IGL) to set up a meter manufacturing plant at an estimated cost of Rs 110 crore. The unit will be set up through a joint venture company, VLF said in a statement on Monday.Genesis Gas Solutions Pvt Ltd (Genesis) has entered into a JV agreement with IGL to set up a smart meter manufacturing plant with a capex of Rs 110 crore, ...
Key Stock Ideas: Genesis, Jindal Stainless, Sun Pharma, Mercedes Benz India - ARETE Securities
Key Stock Ideas: Genesis, Jindal Stainless, Sun Pharma, Mercedes Benz India - ARETE Securities
Source: ARETE Securities Ltd
8/03/2023 9:59:02 AM
Sun Pharma rises on entering into agreements to acquire stakes in Agatsa Software, Remidio Innovative Solutions Sun Pharmaceutical Industries is currently trading at Rs. 986.05, up by 2.50 points or 0.25% from its previous closing of Rs. 983.55 on the BSE. The scrip opened at Rs. 990.00 and has touched a high and low of Rs. 992.15 and Rs. 974.75 respectively. So far 13122 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022. Last one week high and low of the...
Sun Pharma rises on entering into agreements to acquire stakes in Agatsa Software, Remidio Innovative Solutions
Sun Pharma rises on entering into agreements to acquire stakes in Agatsa Software, Remidio Innovative Solutions
Source: Accord Fintech
20/02/2023 10:59:57 AM
Sun Pharma surges on acquiring three anti-inflammatory brands from Aksigen Hospital Care Sun Pharmaceutical Industries is currently trading at Rs. 1048.55, up by 4.95 points or 0.47% from its previous closing of Rs. 1043.60 on the BSE. The scrip opened at Rs. 1035.00 and has touched a high and low of Rs. 1071.90 and Rs. 1035.00 respectively. So far 56152 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022. Last one week high and low ...
Sun Pharma surges on acquiring three anti-inflammatory brands from Aksigen Hospital Care
Sun Pharma surges on acquiring three anti-inflammatory brands from Aksigen Hospital Care
Source: Accord Fintech
30/01/2023 3:17:41 PM
Sun Pharmaceutical Industries rises on launching SEZABY in U.S. Sun Pharmaceutical Industries is currently trading at Rs. 1044.00, up by 4.05 points or 0.39% from its previous closing of Rs. 1039.95 on the BSE. The scrip opened at Rs. 1040.10 and has touched a high and low of Rs. 1050.10 and Rs. 1034.15 respectively. So far 9079 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1070.80 on 02-Nov-2022 and a 52 week low of Rs. 789.75 on 17-Jun-2022. Last one week high and low of...
Sun Pharmaceutical Industries rises on launching SEZABY in U.S.
Sun Pharmaceutical Industries rises on launching SEZABY in U.S.
Source: Accord Fintech
27/01/2023 11:47:33 AM
Buy Sun Pharma Ltd For Target Rs 1,200 - Motilal Oswal Financial Services Concert deal paves way to add JAK inhibitors to specialty portfolio JAK inhibitors have potential to treat multiple skin diseases * Sun Pharma (SUNP) adds Deuroxolitinib, a potential best-in-class JAK inhibitor, to its specialty portfolio through the acquisition of Concert Pharma Inc (CNCE). * Deuroxolitnib has shown a better Severity of Alopecia Tool (SALT) score compared to peers, providing confidence on the potential of the product post regulatory approval. * The deal further ...
Buy Sun Pharma Ltd For Target Rs 1,200 - Motilal Oswal Financial Services
Buy Sun Pharma Ltd For Target Rs 1,200 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
20/01/2023 10:44:05 AM
India's Sun Pharma to acquire U.S.-based Concert for $576 million Sun Pharmaceutical Industries Limited said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to an experimental drug for treating patchy baldness. Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss. India's Sun Pharma said it will commence a tender offer to acquire Concert at $8 per share, a premium of 16% to the stock's la...
India's Sun Pharma to acquire U.S.-based Concert for $576 million
India's Sun Pharma to acquire U.S.-based Concert for $576 million
Source: Reuters
19/01/2023 7:23:34 PM
Digital India emerges top wealth-generation opportunity for Indian retail investors The 'Digital India' theme has emerged as an incredible wealth-generation opportunity for retail investors, investment technology platform WealthDesk said on Wednesday. The 'WealthDesk Year-end Bulletin' underscored that the country has made significant progress in terms of digital friendliness since 2017. As per the bulletin, ITC Ltd., ICICI Bank, Coal India, Sun Pharmaceutical Industries and State Bank of India were the most popular stocks among the 'WealthBasket Cu...
Digital India emerges top wealth-generation opportunity for Indian retail investors
Digital India emerges top wealth-generation opportunity for Indian retail investors
Source: IANS
18/01/2023 6:45:16 PM
Digital India emerges top wealth-generation opportunity for Indian retail investors  The 'Digital India' theme has emerged as an incredible wealth-generation opportunity for retail investors, investment technology platform WealthDesk said on Wednesday. The 'WealthDesk Year-end Bulletin' underscored that the country has made significant progress in terms of digital friendliness since 2017. As per the bulletin, ITC Ltd., ICICI Bank, Coal India, Sun Pharmaceutical Industries and State Bank of India were the most popular stocks among the 'WealthBas...
Digital India emerges top wealth-generation opportunity for Indian retail investors
Digital India emerges top wealth-generation opportunity for Indian retail investors
Source: IANS
18/01/2023 5:29:03 PM
Sun Pharmaceutical Industries jumps on launching Palbociclib in India Sun Pharmaceutical Industries is currently trading at Rs. 1021.70, up by 10.10 points or 1.00% from its previous closing of Rs. 1011.60 on the BSE. The scrip opened at Rs. 1011.10 and has touched a high and low of Rs. 1026.70 and Rs. 1008.05 respectively. So far 50993 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1070.80 on 02-Nov-2022 and a 52 week low of Rs. 785.00 on 25-Jan-2022. Last one week high and low ...
Sun Pharmaceutical Industries jumps on launching Palbociclib in India
Sun Pharmaceutical Industries jumps on launching Palbociclib in India
Source: Accord Fintech
11/01/2023 12:29:44 PM
India's Sun Pharma hit by U.S. FDA import alert on plant, shares drop Sun Pharmaceutical Industries Ltd's drug shipments from its Gujarat plant could be refused entry in its key U.S. market after the drug regulator slapped an import alert on the facility, the drugmaker said on Thursday. The Food and Drug Administration's (FDA) import alert is effectively a ban, implying all future shipments of products made at the plant in Halol, Gujarat could be refused admission to the U.S. market until the facility becomes compliant with the regulator's Curren...
India's Sun Pharma hit by U.S. FDA import alert on plant, shares drop
India's Sun Pharma hit by U.S. FDA import alert on plant, shares drop
Source: Reuters
8/12/2022 12:09:26 PM
Hold Sun Pharmaceutical Industries Ltd For Target Rs .1,002 By - ICICI Securities Sun Pharmaceutical’s (Sun) Q2FY23 performance has been better than our estimates. Consolidated revenues grew 14.7% YoY to Rs109.5bn (I-Sec: Rs105.9bn) and adj. PAT was up 14.3% to Rs22.6bn (I-Sec: Rs18.6bn). EBITDA margin stood at 27.0% (I-Sec: 25.7%). Specialty portfolio grew 5.2% QoQ to US$201mn (I-Sec: US$190mn) led by growth in Ilumya, Cequa and Winlevi. India business (ex-covid) grew ~11% YoY on the back of an increase in overall market share. We remain positive on the company&rsqu...
Hold Sun Pharmaceutical Industries Ltd For Target Rs .1,002 By - ICICI Securities
Hold Sun Pharmaceutical Industries Ltd For Target Rs .1,002 By - ICICI Securities
Source: ICICI Securities Ltd
2/11/2022 12:14:52 PM
India's Sun Pharmaceutical Q2 profit rises 11% Sun Pharmaceutical Industries Ltd, India's largest drugmaker, on Tuesday reported a 10.5% rise in second quarter profit on higher sales in the domestic market. The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said consolidated net profit for three months ended Sept. 30 was 22.62 billion Indian rupees ($273.75 million), up from 20.47 billion rupees last year. Analysts, on average, expected the company to report profit o...
India's Sun Pharmaceutical Q2 profit rises 11%
India's Sun Pharmaceutical Q2 profit rises 11%
Source: Reuters
1/11/2022 2:33:04 PM
Stock Picks - State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct State Bank of India Ltd Buy State Bank of India Ltd @ 552-554 CMP 555.40 Stop Loss 547.40 Target 558.60/564.20   Sun Pharma Ltd Buy Sun Pharma Ltd @ 974-977 CMP 980.35 Stop Loss 964.80 Target 985.30/994.70     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ0...
Stock Picks - State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct
Stock Picks - State Bank of India Ltd and Sun Pharma Ltd By ICICI Direct
Source: ICICI Direct
21/10/2022 11:34:51 AM
Vikram Samvat 2079 Diwali Technical Picks By Sumeet Bagadia, Choice Broking NMDC • On a monthly chart, the stock has been trading with higher highs & higher low formations which suggests an upside rally in the counter. • Furthermore, the stock has been trading with the support of 50 MMA which suggests a positive bias. • On a daily chart, the stock has been trading in a rising wedge formation and tested the lower band of formation which points out. • A daily momentum indicator Stochastic shows a positive crossover which adds more bu...
Vikram Samvat 2079 Diwali Technical Picks By Sumeet Bagadia, Choice Broking
Vikram Samvat 2079 Diwali Technical Picks By Sumeet Bagadia, Choice Broking
Source: Choice Broking Pvt Ltd
15/10/2022 6:08:16 PM
Stock Picks - Sun Pharma Ltd and Indigo Ltd By ICICI Direct Sun Pharma Ltd Buy Sun Pharma Ltd @ 948.00-952.00 CMP 955.15 Stop Loss 941.20 Target 959.40/967.90   Indigo Ltd Buy Indigo Ltd @ 1781-1784 CMP 1794.10 Stop Loss 1799.50 Target 1765.40/1748.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the...
Stock Picks - Sun Pharma Ltd and Indigo Ltd By ICICI Direct
Stock Picks - Sun Pharma Ltd and Indigo Ltd By ICICI Direct
Source: ICICI Direct
10/10/2022 11:16:14 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1080 - Religare Broking Sun Pharmaceutical Industries Ltd. (SUNPHARMA) * Sunpharma had been among the top performing counters till 2015 however a prolonged corrective phase of nearly 5 years pushed the stock from its record high of 1058.71 and made a low of 300 levels in March 2020. * It finally witnessed a reversal in April 2020 and made a steady recovery in the following months to retest the record high zone in April 2022. * It was trading in a consolidation range around the record high for the last five ...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1080 - Religare Broking
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1080 - Religare Broking
Source: Religare Broking Ltd
30/09/2022 11:46:15 AM
Stock Picks - Sun Pharma Ltd and Dabur India Ltd By ICICI Direct Sun Pharma Ltd Buy Sun Pharma Ltd @ 901.00-904.00 CMP 908.00 Stop Loss 893 Target 910.80/919.80   Dabur India Ltd Buy Dabur India Ltd @ 901.00-904.00 CMP 908.00 Stop Loss 893 Target 910.80/919.80   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the author and not ...
Stock Picks - Sun Pharma Ltd and Dabur India Ltd By ICICI Direct
Stock Picks - Sun Pharma Ltd and Dabur India Ltd By ICICI Direct
Source: ICICI Direct
23/09/2022 10:43:05 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,100 - Motilal Oswal Superior execution across key segments Yet to see increased R&D spend in the Specialty portfolio * SUNP delivered a strong beat on 1QFY23 earnings, led by broad based growth across business segments (US/Domestic Formulation (DF)/emerging markets (EMs)/RoW). While lower R&D spends has further enhanced margin in 1QFY23. However, the postponement of clinical trials would delay in obtaining potential approvals/subsequent commercial benefit from new chemical entity (NCE) assets. &...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,100 - Motilal Oswal
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,100 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
12/09/2022 9:25:38 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1,050 - Centrum Broking Specialty scaling up Sun Pharma 1QFY23 revenues stood at Rs 106.4bn up 10% YoY, which was in-line with our estimates. US revenues US$ 420mn (up 10.6% YoY) and India sales of Rs 33.9bn (up 2.4% YoY). Taro sales rose 9.4% QoQ to USD 157mn and Emerging markets sales were up 17.8% YoY. Revenue traction has supported 25.4% EBITDA margin, amid cost escalations, Winlevi launch expenses and normalization of operations in India. the company had a forex gain of Rs1.5bn, adjusted to this, PAT came in...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1,050 - Centrum Broking
Buy Sun Pharmaceutical Industries Ltd. For Target Rs.1,050 - Centrum Broking
Source: Centrum Broking Ltd
5/09/2022 2:07:47 PM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,130 - JM Financial Institutional Securities Ltd Double-digit growth with expanding margins SUNP reported stellar performance with highest global specialty revenue of USD 191 mn driven by Ilumya, Cequa, Odomzo and Winlevi in a seasonally weak quarter. Revenue/ EBITDA/ Adj. PAT of INR 107618 mn/ 28844 mn/ 20609 mn were +11%/+2%/+4% YoY and were +7%/+11%/+12% vs. our estimates. Overall sales growth was in healthy double digits i.e. 14% (ex-Covid). EBITDA margins increased c. 200 bps QoQ to 26.8% (+110 bps beat) amid inflationary pressures ...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,130 - JM Financial Institutional Securities Ltd
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,130 - JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
19/08/2022 2:44:30 PM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance Highlights from the Quarter (Q1 FY23) Consolidated sales for the quarter were at Rs.10,761.8 cr recording a growth of about 10.7% yoy. US sales grew at a healthy pace at 16% growth yoy. The growth was driven by a combination of healthy growth in the specialty segment and generics. Sun ex-Taro generics business has recorded growth both on YoY and QoQ basis. This growth is driven by a combination of new launches, market share gains for existing products and better supply chain management. Do...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance
Source: Sushil Finance Ltd
16/08/2022 3:28:20 PM
Sun Pharma jumps on reporting 43% rise in Q1 consolidated net profit Sun Pharma is currently trading at Rs. 941.10, up by 46.35 points or 5.18% from its previous closing of Rs. 894.75 on the BSE. The scrip opened at Rs. 894.00 and has touched a high and low of Rs. 951.25 and Rs. 879.00 respectively. So far 442541 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 680.75 on 29-Jul-2021. Last one week high and low of the scrip stood at Rs...
Sun Pharma jumps on reporting 43% rise in Q1 consolidated net profit
Sun Pharma jumps on reporting 43% rise in Q1 consolidated net profit
Source: Accord Fintech
29/07/2022 3:30:15 PM
Sun Pharma`s US-based unit recalls 50,680 vials of Testosterone Cypionate Injection Sun Pharmaceutical Industries’ US-based unit is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market. The company is recalling the affected lot due to 'water leakage' leading to deviation from current good manufacturing practices (cGMP). The company is also recalling 27 vials of the same medication due to cGMP deviations. The affected lot was produced at Sun Pharma's Halol (Gujarat) based manufactur...
Sun Pharma`s US-based unit recalls 50,680 vials of Testosterone Cypionate Injection
Sun Pharma`s US-based unit recalls 50,680 vials of Testosterone Cypionate Injection
Source: Accord Fintech
25/07/2022 10:22:19 AM
Stock Picks - Sun Pharmaceutical Industries Ltd and Aditya Birla Fashion and Retail Ltd By ICICI Direct Sun Pharmaceutical Industries Ltd Buy Sun Pharmaceutical Industries Ltd @ 876.00-879.00 CMP 882.80 Stop Loss 869.30 Target 885.40/893.00   Aditya Birla Fashion & Retail Buy Aditya Birla Fashion & Retail @  259.00-261.00 CMP 261.55 Stop Loss 257.20 Target 262.40/265.00     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https...
Stock Picks - Sun Pharmaceutical Industries Ltd and Aditya Birla Fashion and Retail Ltd By ICICI Direct
Stock Picks - Sun Pharmaceutical Industries Ltd and Aditya Birla Fashion and Retail Ltd By ICICI Direct
Source: ICICI Direct
19/07/2022 10:56:23 AM
Even amid pullout, FIIs have raised their stake in certain companies Foreign investors pulling out money from the Indian equity segment had made several headlines in the recent months. Pulling out over $42 billion or Rs 3.26 lakh crore from the Indian markets in the last eight months, foreign investors have been net-sellers in the Indian market during these straight months. FPIs have been selling across the board, though with some sectors seeing more pressure and some others less. The underlying reason behind the pullout is that the stock market has b...
Even amid pullout, FIIs have raised their stake in certain companies
Even amid pullout, FIIs have raised their stake in certain companies
Source: IANS
18/06/2022 1:22:36 PM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance Sun Pharmaceutical Industries Ltd.(Sun Pharma) recently announced its performance for the quarter ended Mar.31, 22. Following are the key highlights. Highlights from the Quarter (Q4 FY22) Consolidated sales for the quarter were at Rs.9,446.8 cr recording a growth of about 10.8% yoy. Domestic sales grew at a healthy pace at 16% growth yoy. The growth was driven by a combination of factors like normalized market condition and improved patient flow to doctor's clinics. The company focu...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1000 - Sushil Finance
Source: Sushil Finance Ltd
3/06/2022 11:44:53 AM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,050 - Motilal Oswal The USFDA reinspection at Halol – a mixed bag Resolution of the media fill-related issue remains a key monitorable * Recently, the USFDA inspected the Halol site of Sun Pharmaceutical Industries (SUNP) and issued Form 483 with 10 observations * The observations were largely related to media-fill studies, improvement in aseptic operations, cleaning & maintenance of equipment, personnel training and inadequate root cause analysis. * Halol contributed about 3-4% of SUNP&rsq...
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,050 - Motilal Oswal
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 1,050 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
16/05/2022 12:05:38 PM
Sun Pharma soars on getting USFDA nod for generic Mesalamine extended release capsules Sun Pharmaceutical Industries is currently trading at Rs. 873.10, up by 22.95 points or 2.70% from its previous closing of Rs. 850.15 on the BSE. The scrip opened at Rs. 850.60 and has touched a high and low of Rs. 881.40 and Rs. 850.60 respectively. So far 23822 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 652.75 on 18-Jun-2021. Last one week high and low of the...
Sun Pharma soars on getting USFDA nod for generic Mesalamine extended release capsules
Sun Pharma soars on getting USFDA nod for generic Mesalamine extended release capsules
Source: Accord Fintech
13/05/2022 9:50:26 AM
Sun Pharma gains on inking pact with Lundbeck to market, distribute Vortioxetine in India Sun Pharmaceutical Industries is currently trading at Rs. 920.05, up by 0.55 points or 0.06% from its previous closing of Rs. 919.50 on the BSE. The scrip opened at Rs. 920.00 and has touched a high and low of Rs. 921.95 and Rs. 908.30 respectively. So far 66897 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.90 on 21-Mar-2022 and a 52 week low of Rs. 587.50 on 30-Mar-2021. Last one week high and low of the ...
Sun Pharma gains on inking pact with Lundbeck to market, distribute Vortioxetine in India
Sun Pharma gains on inking pact with Lundbeck to market, distribute Vortioxetine in India
Source: Accord Fintech
30/03/2022 3:26:41 PM
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 955 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 955 - Religare Broking
Buy Sun Pharmaceutical Industries Ltd. For Target Rs. 955 - Religare Broking
Source: Religare Broking Ltd
21/03/2022 11:33:09 AM